Erica Stringer-Reasor is an Oncology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 170 publications with 7,682 citations (h-index 29); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 6th Ave S
Birmingham, AL 352331801
Telephone
800-822-8816Registry record last updated 29 Jun 2023.
Clinical trials
4 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Gilead Sciences, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
88.1%Aromatase Inhibitor73.8%Anastrozole63%Letrozole23%Exemestane14%Part D≥138 patientsKinase inhibitor8.4%Verzenio65%Ibrance35%Part D<11 patients+ 1 more class in this area
Nervous system
5.1%Gabapentinoids2.3%Gabapentin100%Part D≥13 patientsSNRI1.6%Venlafaxine Hcl Er100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
4.3%Serotonin-3 Receptor Antagonist2.4%Ondansetron Hcl100%Part D≥22 patientsPotassium supplement1.8%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Journal of the National Comprehensive Cancer Network
2025 - Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”